OverviewSuggest Edit

Retrophin is a biopharmaceutical company which focuses on the development, acquisition, and commercialization of therapies for the treatment of serious or rare diseases. Its marketed products include Chenodal, Cholbam and Thiola. The Company also has a number of product candidates to treat various serious diseases.

TypePublic
Founded2011
HQSan Diego, US
Websiteretrophin.com
Employee Ratings4.2

Latest Updates

Employees (est.) (Jan 2020)221(+4%)
Job Openings27
Revenue (FY, 2019)$175.3 M(+7%)
Share Price (Sept 2020)$18.7
Cybersecurity ratingBMore

Key People/Management at Retrophin

Eric Dube

Eric Dube

Director, President and Chief Executive Officer
Gary A. Lyons

Gary A. Lyons

Chairman
Peter Heerma

Peter Heerma

Chief Commercial Officer
Laura M. Clague

Laura M. Clague

Chief Financial Officer
Noah L. Rosenberg

Noah L. Rosenberg

Chief Medical Officer
Tim Coughlin

Tim Coughlin

Director
Show more

Retrophin Office Locations

Retrophin has offices in San Diego, Cambridge and Dublin
San Diego, US (HQ)
3721 Valley Centre Dr #200
Cambridge, US
141 Portland St 10th Floor
Dublin, IE
2nd Floor Palmerston House Fenian Street
Show all (3)

Retrophin Financials and Metrics

Retrophin Revenue

Retrophin's revenue was reported to be $175.34 m in FY, 2019
USD

Revenue (Q2, 2020)

48.4m

Gross profit (Q2, 2020)

46.9m

Gross profit margin (Q2, 2020), %

96.9%

Net income (Q2, 2020)

(26.1m)

EBIT (Q2, 2020)

(23.1m)

Market capitalization (22-Sept-2020)

953.0m

Closing stock price (22-Sept-2020)

18.7

Cash (30-Jun-2020)

237.2m

EV

925.8m
Retrophin's current market capitalization is $953 m.
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

28.2m99.9m133.6m154.9m164.2m175.3m

Revenue growth, %

254%34%

Cost of goods sold

12.0k571.0k2.2m4.6m3.6m5.5m5.2m

Gross profit

(12.0k)27.6m97.7m129.0m151.3m158.7m170.1m
Quarterly
USDQ2, 2012Q3, 2012Q2, 2013Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

27.9k5.7m8.3m17.4m24.1m29.0m33.3m33.9m33.6m38.8m40.3m38.4m41.3m40.7m39.6m44.7m44.4m47.8m48.4m

Cost of goods sold

900.01.2m197.4k274.4k637.0k513.0k757.0k1.0m1.6m709.0k797.0k925.0k1.6m1.2m1.1m1.0m979.0k1.5m1.5m

Gross profit

27.0k4.5m8.2m17.1m23.4m28.3m32.3m32.4m32.9m38.0m39.4m36.8m40.2m39.6m38.6m43.7m42.9m46.9m

Gross profit Margin, %

97%79%98%98%97%97%97%95%98%98%98%96%97%97%97%98%97%97%
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

3.9k6.0m18.2m37.8m41.0m99.4m102.9m62.4m

Accounts Receivable

8.0m12.5m18.5m13.9m14.5m18.0m

Prepaid Expenses

1.4m813.4k2.4m3.1m2.3m5.0m

Inventories

800.5k2.5m2.8m5.4m5.6m6.1m
Show all financial metrics

Retrophin Cybersecurity Score

Cybersecurity ratingPremium dataset

B

81/100

SecurityScorecard logo

Retrophin Online and Social Media Presence

Embed Graph

Retrophin News and Updates

Retrophin Announces Enrollment of First 280 Patients in Pivotal Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy

Topline data from 36-week proteinuria endpoint anticipated in third quarter of 2021 Topline data from 36-week proteinuria endpoint anticipated in third quarter of 2021

Retrophin to Present at the BMO 2020 Prescriptions for Success Healthcare Conference

SAN DIEGO, June 19, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Eric Dube, Ph.D., chief executive officer, will present at the BMO 2020 Prescriptions for Success Healthcare Conference on Tuesday, June 23, 2020 at 10:00 a.m. ET.

Retrophin Announces Pricing of Public Offering of Common Stock

SAN DIEGO, June 08, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq: RTRX) today announced the pricing of an underwritten public offering of 6,500,000 shares of its common stock at a price to the public of $15.50 per share. All of the shares are being sold by Retrophin. The gross proceeds from th…

Retrophin Reports Fourth Quarter and Full Year 2019 Financial Results

Pivotal DUPLEX and PROTECT studies of sparsentan enrolling towards topline readouts to support potential NDA and CMA filings

Retrophin Provides Corporate Update and 2020 Outlook

SAN DIEGO, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that, based on preliminary and unaudited financial data, the Company expects net product sales for the fourth quarter of 2019 to be approximately $47 million. For the fiscal year 2019, the Company expects t…

Retrophin neurological disorder drug misses late-stage study main goal

Retrophin Inc said on Thursday its treatment for a rare neurological disorder failed to meet the main goal in a late-stage study.
Show more

Retrophin Blogs

Retrophin Frequently Asked Questions

  • When was Retrophin founded?

    Retrophin was founded in 2011.

  • Who are Retrophin key executives?

    Retrophin's key executives are Eric Dube, Gary A. Lyons and Peter Heerma.

  • How many employees does Retrophin have?

    Retrophin has 221 employees.

  • What is Retrophin revenue?

    Latest Retrophin annual revenue is $175.3 m.

  • What is Retrophin revenue per employee?

    Latest Retrophin revenue per employee is $793.4 k.

  • Who are Retrophin competitors?

    Competitors of Retrophin include Albumedix, Ventria Bioscience and Acticor Biotech.

  • Where is Retrophin headquarters?

    Retrophin headquarters is located at 3721 Valley Centre Dr #200, San Diego.

  • Where are Retrophin offices?

    Retrophin has offices in San Diego, Cambridge and Dublin.

  • How many offices does Retrophin have?

    Retrophin has 3 offices.